Zobrazeno 1 - 10
of 23
pro vyhledávání: ''
Publikováno v:
Gut. 68(10)
A 27-year-old man was admitted to our department because of persistent symptoms of fever, dyspnoea, dry cough, elevated C reactive protein (CRP) (258 mg/L), leucocytosis (17×109/L), peripheral eosinophilia (29%) and elevated liver enzymes (alanine a
Autor:
Erwin Daniel Brenndörfer, Anette Brass, Lars Frelin, Matti Sällberg, Soo Aleman, Johannes G. Bode, Jonas Söderholm
Publikováno v:
Gut. 61:589-596
Background The non-structural (NS) 3/4A protease/helicase of the hepatitis C virus is known to modulate signalling pathways in the infected hepatocyte by cleaving CARD adaptor inducing IFNβ (Cardif), T-cell protein tyrosine phosphatase (TC-PTP) and
Autor:
Ingrid Laurendeau, Audrey Sabbagh, Ivan Bièche, Dominique Valla, Marie-Pierre Ripault, Michèle Martinot-Peignoux, Stéphanie Narguet, Patrick Marcellin, Nathalie Boyer, Michel Vidaud, Tarik Asselah
Publikováno v:
Gut. 57:516-524
Background and Aims The gold standard treatment of chronic hepatitis C is the combination of pegylated interferon plus ribavirin. Considering side effects and treatment cost, prediction of treatment response before therapy is important. The aim of ou
Publikováno v:
Gut. 49:860-863
BACKGROUND—Strategies for prevention of liver graft reinfection by hepatitis B virus (HBV) have been developed during recent years. Initially, passive immunoprophylaxis with high titre HBV immunoglobulin (HBIg), followed by lamivudine prophylaxis,
Publikováno v:
Gut. 66:322-322
A 67-year-old man presented to our centre 5 years ago with a short history of jaundice and weight loss. A diagnosis of autoimmune hepatitis was made following laboratory investigations, imaging and a trans-jugular liver (TJ) biopsy. He was treated wi
Publikováno v:
Gut. 34:S121-S123
Chronic hepatitis C virus (HCV) associated liver disease is an important cause of morbidity and mortality in haemophilia. Recombinant interferon alfa-2b was used in a randomised controlled liver biopsy trial to treat haemophiliacs with chronic HCV. A
Autor:
Robert Dick, AP Dhillon, Keith Rolles, S. Bhattacharya, Brian R. Davidson, J Saada, A.K. Burroughs
Publikováno v:
Gut. 41(3)
Background—The detection of hepatocellular cancers (HCC) is a major role of preoperative imaging in patients with end stage liver disease being considered for orthotopic liver transplantation (OLT).Aims—To assess the sensitivity of iodised oil co
Autor:
S. A. Jenkins, S K Vyas, A J Turnbull, Elwyn Elias, John P. Iredale, Oliver F. W. James, Robert Sutton, M F Bassendine, M J P Arthur, R Shields, M Davies, Andrew N. Kingsnorth
Publikováno v:
Gut. 41(4)
Background—Few studies have compared vasoactive drugs with endoscopic sclerotherapy in the control of acute variceal haemorrhage. Octreotide is widely used for this purpose, but its value remains undetermined.Aims—To compare octreotide with endos
Autor:
D. Renda, Marcello Capra, O. Lo Iacono, S. Grutta, Aurelio Maggio, V. Di Marco, C. Ciaccio, Calogera Gerardi, P.L. Almasio, R. Pisa
Publikováno v:
Gut. 34
In this open, pilot study, interferon (IFN) alpha-2b seemed effective in the treatment of hepatitis C virus (HCV) infection in patients with beta-thalassaemia. In seven of nine patients who completed the study alanine aminotransferase activities retu
Publikováno v:
Gut. 34
In a study of 60 patients with non-A, non-B/type C (NANB/C) chronic hepatitis alanine aminotransferase (ALT) activities returned to normal after treatment with interferon alfa-2b (3 million units for six months) in 70.7% and 29.3% did not respond. Th